Approach to diagnosis and treatment of hypercalcemia in a patient with malignancy

American Journal of Kidney Diseases

Volumn 63, Issue 1, 2014, Pages 141-147

  Reagan, Patrick ^a   Pani, Antonello ^b   Rosner, Mitchell H ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b BROTZU HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CETUXIMAB; CISPLATIN; CLINDAMYCIN; COTRIMOXAZOLE; FLUOROURACIL; PAMIDRONIC ACID; PARATHYROID HORMONE; VITAMIN D;

AGED; AMNESIA; ARTICLE; CALCIUM BLOOD LEVEL; CANCER CHEMOTHERAPY; CASE REPORT; CHEEK MUCOSA; COMPUTER ASSISTED TOMOGRAPHY; CONFUSION; EMERGENCY WARD; FOLLOW UP; HUMAN; HYPERCALCEMIA; LABORATORY TEST; LETHARGY; LOCAL METASTASIS; MALE; MEDICAL HISTORY; NOCTURIA; POLYDIPSIA; POLYURIA; SHORT TERM MEMORY; SQUAMOUS CELL CARCINOMA; THIRST;

BISPHOSPHONATE; CANCER; HYPERCALCEMIA; PARATHYROID HORMONE-RELATED PROTEIN;

AGED; ANTINEOPLASTIC AGENTS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CARCINOMA, SQUAMOUS CELL; DIPHOSPHONATES; HUMANS; HYPERCALCEMIA; KIDNEY; MALE; MOUTH MUCOSA; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; PARATHYROID HORMONE-RELATED PROTEIN; REHYDRATION SOLUTIONS; SODIUM CHLORIDE; TREATMENT OUTCOME;

EID: 84896545864     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2013.06.025     Document Type: Article

References (45)

1. A.F. Stewart Clinical practice. hypercalcemia associated with cancer N Engl J Med 352 4 2005 373 379
2. M.H. Rosner, and A.C. Dalkin Onco-nephrology: the pathophysiology and treatment of malignancy-associated hypercalcemia Clin J Am Soc Nephrol 7 10 2012 1722 1729
3. R. Vassilopoulou-Sellin, B.M. Newman, S.H. Taylor, and V.F. Guinee Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center Cancer 71 4 1993 1309 1312
4. F. Bringhurst, M.B. Demay, and H.M. Kronenberg Hormones and disorders of mineral metabolism S. Melmed, K.S. Polonsky, P.R. Larsen, H.M. Kronenberg, Williams Textbook of Endocrinology 12th ed. 2011 WB Saunders St Louis, MO 1237 1257
5. G.J. Strewler The physiology of parathyroid hormone-related protein N Engl J Med 342 3 2000 177 185
6. M.J. Horwitz, M.B. Tedesco, and S.M. Sereika et al. Continuous PTH and PTHrP infusion causes suppression of bone formation and discordant effects on 1,25(OH)2 vitamin D J Bone Miner Res 20 10 2005 1792 1803
7. T. Dean, J.P. Vilardaga, J.T. Potts Jr., and T.J. Gardella Altered selectivity of parathyroid hormone (PTH) and PTH-related protein (PTHrP) for distinct conformations of the PTH/PTHrP receptor Mol Endocrinol 22 1 2008 156 166
8. J.J. Wysolmerski Parathyroid hormone-related protein: an update J Clin Endocrinol Metab 97 9 2012 2947 2956
9. A.C. Hutchesson, N.J. Bundred, and W.A. Ratcliffe Survival in hypercalcemic patients with cancer and co-exisiting primary hyperparathyroidism Postgrad Med J 71 831 1995 29 31
10. A.F. Stewart, R. Horst, L.J. Deftos, E.C. Cadman, R. Lang, and A.E. Broadus Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and nonhumoral groups N Engl J Med 303 24 1980 1377 1383
11. M.A. Syed, M.J. Horwitz, M.B. Tedesco, A. Garcia-Ocana, S.R. Wisniewski, and A.F. Stewart Parathyroid hormone-related protein-(1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy J Clin Endocrinol Metab 86 4 2001 1525 1531
12. M.J. Horwitz, M.B. Tedesco, S.M. Sereika, B.W. Hollis, A. Garcia-Ocana, and A.F. Stewart Direct comparison of sustained infusion of human parathyroid hormone-related protein-(1-36) [hPTHrP-(1-36)] versus hPTH-(1-34) on serum calcium, plasma 1,25-dihydroxyvitamin D concentrations, and fractional calcium excretion in healthy human volunteers J Clin Endocrinol Metab 88 4 2003 1603 1609
13. M. Akhtari, J. Mansuri, K.A. Newman, T.M. Guise, and P. Seth Biology of breast cancer bone metastasis Cancer Biol Ther 7 1 2008 3 9
14. R.W. Johnson, M.P. Nguyen, and S.S. Padalecki et al. TGF-β promotion of Gli2-induced expression of parathyroid hormone-related protein, an important osteolytic factor in bone metastasis, is independent of canonical Hedgehog signaling Cancer Res 71 3 2011 822 831
15. J.L. Sanders, N. Chattopadhyay, O. Kifor, T. Yamaguchi, R.R. Butters, and E.M. Brown Extracellular calcium-sensing receptor expression and its potential role in regulating parathyroid hormone-related peptide secretion in human breast cancer cell lines Endocrinology 141 12 2000 4357 4364
16. G.D. Roodman Mechanisms of bone lesions in multiple myeloma and lymphoma Cancer 80 suppl 8 1997 1557 1563
17. G.D. Roodman Pathogenesis of myeloma bone disease J Cell Biochem 109 2 2010 283 291
18. J.N. VanHouten, N. Yu, and D. Rimm et al. Hypercalcemia of malignancy due to ectopic transactivation of the parathyroid hormone gene J Clin Endocrinol Metab 91 2 2006 580 583
19. H.R. Toka, Al-Romaih, and J.M. Koshy et al. Deficiency of the calcium-sensing receptor in the kidney causes parathyroid hormone-independent hypocalciuria J Am Soc Nephrol 23 11 2012 1879 1890
20. S.B. LeGrand, D. Leskuski, and I. Zama Narrative review: furosemide for hypercalcemia: an unproven yet common practice Ann Intern Med 149 4 2008 259 263
21. W.N. Suki, J.J. Yium, M. Von Minden, C. Saller-Hebert, G. Eknoyan, and M. Martinez-Maldonado Acute treatment of hypercalcemia with furosemide N Engl J Med 283 16 1970 836 840
22. H. Fleisch Bisphosphonates: mechanisms of action Endocr Rev 19 1 1998 80 100
23. E. Hiroi-Furuya, T. Kameda, and K. Hiura et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts Calcif Tissue Int 64 3 1999 219 223
24. D. Amin, S.A. Cornell, and S.K. Gustafson et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis J Lipid Res 33 11 1992 1657 1663
25. P. Major, A. Lortholary, and J. Hon et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials J Clin Oncol 19 2 2001 558 567
26. S.R. Nussbaum, J. Younger, and C.J. Vandepol et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosages Am J Med 95 3 1993 297 304
27. D.J. Dodwell, A. Howell, A.R. Morton, P.T. Daley-Yates, and C.R. Hoggarth Infusion rate and pharmacokinetics of intravenous pamidronate in the treatment of tumour-induced hypercalcaemia Postgrad Med J 68 800 1992 434 439
28. R. Desikan, Y. Veksler, and S. Raza et al. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma Br J Haematol 119 2 2002 496 499
29. G.S. Markowitz, P.L. Fine, and V.D. D'agati Nephrotic syndrome after treatment with pamidronate Am J Kidney Dis 39 5 2002 1118 1122
30. M. Bodmer, P. Amico, and M.J. Mihatsch et al. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient Nephrol Dial Transplant 22 8 2007 2366 2370
31. G.S. Markowitz, G.B. Appel, and P.L. Fine et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate J Am Soc Nephrol 12 6 2001 1164 1172
32. G.S. Markowitz, P.L. Fine, and J.I. Stack et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa) Kidney Int 64 1 2003 281 289
33. C.B. Vaughn, and V.K. Vaitkevicius The effects of calcitonin in hypercalcemia in patients with malignancy Cancer 34 4 1974 1268 1271
34. M.L. Binstock, and G.R. Mundy Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy Ann Intern Med 93 2 1980 269 272
35. T.J. Hall, and T.J. Chambers Gallium inhibits bone resorption by a direct effect on osteoclasts Bone Miner 8 3 1990 211 216
36. R.P. Warrell Jr., R.S. Bockman, C.J. Coonley, M. Isaacs, and H. Staszewski Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia J Clin Invest 73 5 1984 1487 1490
37. R.P. Warrell Jr., N.W. Alcock, and R.S. Bockman Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases J Clin Oncol 5 2 1987 292 298
38. R.P. Warrell Jr., R. Israel, M. Frisone, T. Snyder, J.J. Gaynor, and R.S. Bockman Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin Ann Intern Med 108 5 1988 669 674
39. F. Cvitkovic, J.P. Armand, M. Tubiana-Hulin, J.F. Rossi, and R.P. Warrell Jr. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia Cancer J 12 1 2006 47 53
40. D.H. Henry, L. Costa, and F. Goldwasser et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 9 2011 1125 1132
41. K. Fizazi, M. Carducci, and M. Smith et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 9768 2011 813 822
42. S.A. Boikos, and H.J. Hammers Denosumab for the treatment of bisphosphonate-refractory hypercalcemia J Clin Oncol 30 29 2012 e299
43. A.S. Levey, J. Coresh, T. Greene Chronic Kidney Disease Epidemiology Collaboration Using standardized serum creatinine values in the Modification Of Diet in Renal Disease Study equation for estimating glomerular filtration rate Ann Intern Med 145 4 2006 247 254
44. S.E. Chistensen, P.H. Nissen, P. Vestergaard, and L. Mosekilde Familial hypocakciuric hypercalcemia: a review Curr Opin Endocrinol Diabetes Obes 18 6 2011 359 370
45. S.E. Christensen, P.H. Nissen, P. Vestergaard, L. Heickendorff, K. Brixen, and L. Mosekilde Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods Clin Endocrinol (Oxf) 69 5 2008 713 720